ATE225177T1 - Verwendung von (+)mefloquine zur behandlung von malaria - Google Patents

Verwendung von (+)mefloquine zur behandlung von malaria

Info

Publication number
ATE225177T1
ATE225177T1 AT98910836T AT98910836T ATE225177T1 AT E225177 T1 ATE225177 T1 AT E225177T1 AT 98910836 T AT98910836 T AT 98910836T AT 98910836 T AT98910836 T AT 98910836T AT E225177 T1 ATE225177 T1 AT E225177T1
Authority
AT
Austria
Prior art keywords
quinolinemethanol
piperidinyl
trifluoromethyl
alpha
bis
Prior art date
Application number
AT98910836T
Other languages
German (de)
English (en)
Inventor
Robin Shepherd
Allan Fletcher
Original Assignee
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704809.4A external-priority patent/GB9704809D0/en
Priority claimed from GBGB9722232.7A external-priority patent/GB9722232D0/en
Priority claimed from GBGB9724263.0A external-priority patent/GB9724263D0/en
Priority claimed from GBGB9724712.6A external-priority patent/GB9724712D0/en
Application filed by Vernalis Res Ltd filed Critical Vernalis Res Ltd
Application granted granted Critical
Publication of ATE225177T1 publication Critical patent/ATE225177T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98910836T 1997-03-07 1998-03-06 Verwendung von (+)mefloquine zur behandlung von malaria ATE225177T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9704809.4A GB9704809D0 (en) 1997-03-07 1997-03-07 Chemical compounds
GBGB9722232.7A GB9722232D0 (en) 1997-10-21 1997-10-21 Chemical compounds
GBGB9724263.0A GB9724263D0 (en) 1997-11-17 1997-11-17 Chemical compounds
GBGB9724712.6A GB9724712D0 (en) 1997-11-21 1997-11-21 Chemical compounds
PCT/GB1998/000675 WO1998039003A1 (en) 1997-03-07 1998-03-06 Use of (+)mefloquine for the treatment of malaria

Publications (1)

Publication Number Publication Date
ATE225177T1 true ATE225177T1 (de) 2002-10-15

Family

ID=27451612

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98910836T ATE225177T1 (de) 1997-03-07 1998-03-06 Verwendung von (+)mefloquine zur behandlung von malaria

Country Status (10)

Country Link
US (1) US6664397B1 (https=)
EP (1) EP0966285B1 (https=)
JP (1) JP4380800B2 (https=)
AT (1) ATE225177T1 (https=)
AU (1) AU730818B2 (https=)
DE (1) DE69808440T2 (https=)
DK (1) DK0966285T3 (https=)
ES (1) ES2185153T3 (https=)
PT (1) PT966285E (https=)
WO (1) WO1998039003A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0975345A1 (en) * 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
GB0021776D0 (en) 2000-09-05 2000-10-18 Arakis Ltd The treatment of inflammatory disorders
GB0406014D0 (en) * 2004-03-17 2004-04-21 Arakis Ltd Pharmaceutical composition and use
WO2006138487A2 (en) * 2005-06-14 2006-12-28 The Johns Hopkins University Treatment of ischemia-induced arrhythmias
RU2008135762A (ru) * 2006-02-16 2010-03-27 Де МакЛин Хоспитал Корпорейшн (US) Способы и композиции для лечения болезни паркинсона
US20110039888A1 (en) * 2008-04-21 2011-02-17 Coltart Don M Asymmetric alpha functionalization and alpha, alpha bisfunctionalization of aldehydes and ketones
EP2411003A4 (en) * 2009-03-24 2012-10-17 Univ Singapore USE OF ARTEMISININE DERIVATIVES IN THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE BRONCHO-PNEUMOPATHY (COPD)
WO2012068560A2 (en) 2010-11-18 2012-05-24 Jenrin Discovery 4-quinolinemethanols as anti-malarial agents
EP2487157A1 (en) 2011-02-11 2012-08-15 Université de Picardie Jules Verne Enantioselective synthesis method of 4-aminoalcoholquinoline derivatives and the use
JP6140825B2 (ja) * 2012-08-09 2017-05-31 キャン−ファイト バイオファーマ リミテッドＣａｎ−Ｆｉｔｅ ＢｉｏＰｈａｒｍａ Ｌｔｄ． 性機能不全の治療に使用するためのａ３アデノシン受容体リガンド
CN103304538B (zh) * 2013-06-21 2014-12-24 中国人民解放军第四军医大学 右旋甲氟喹的合成
CN107149601B (zh) * 2017-05-25 2020-04-17 中国中医科学院中药研究所 青蒿素类化合物在制备治疗神经病理性疼痛和/或并发症的药物中的应用
CN111527068A (zh) 2017-11-03 2020-08-11 皮卡第儒勒-凡尔纳大学 新型氨基吡啶甲醇化合物及其用途
CN110507646A (zh) * 2019-09-12 2019-11-29 广州中医药大学(广州中医药研究院) 青蒿素衍生物在制备抗焦虑症的药物或缓解焦虑症的食品中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE2940443A1 (de) 1979-10-05 1981-04-16 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von erythro-(alpha)-2-piperidyl-2,8-bis-(trifluormethyl)-4-chinolin-methanol
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system

Also Published As

Publication number Publication date
AU730818B2 (en) 2001-03-15
ES2185153T3 (es) 2003-04-16
JP2001526637A (ja) 2001-12-18
JP4380800B2 (ja) 2009-12-09
DE69808440D1 (de) 2002-11-07
EP0966285B1 (en) 2002-10-02
AU6506898A (en) 1998-09-22
DK0966285T3 (da) 2002-10-28
EP0966285A1 (en) 1999-12-29
US6664397B1 (en) 2003-12-16
PT966285E (pt) 2002-12-31
HK1024631A1 (en) 2000-10-20
WO1998039003A1 (en) 1998-09-11
DE69808440T2 (de) 2003-07-10

Similar Documents

Publication Publication Date Title
ATE225177T1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
FI973163A0 (fi) Pidätyskyvyttömyyden hoitaminen käyttämällä (S)-oksibutyniiniä ja (S)-desetyylioksibutyniiniä
EA200700232A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
DK1223980T3 (da) Anvendelse af CSF-1-inhibitorer
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
SE9701144D0 (sv) Novel compounds, their use and preparation
ATE493978T1 (de) Behandlung von autoimmunerkrankungen
DK0998287T3 (da) Anvendelse af levobupivacain
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
ATE251139T1 (de) (+)-norcisapride verwendbar bei 5-ht3 und 5-ht4 bedingten krankheiten
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE446748T1 (de) Verwendung von r-carprofen zur vorbeugung der alzheimerschen krankheit
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
DK1000046T3 (da) Piperazinderivater, der er aktive på den nedre urinvejskanal
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
DE69729201D1 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
PT900082E (pt) Utilizacao de piridilpiperazina e pirimidilpiperazina para o fabrico de um medicamento para o tratamento de perturbacoes de toxicomania
DE60121978D1 (de) 7-CHLOR-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON SCHMERZEN
DE69910706D1 (de) Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie
CA2387394A1 (en) Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0966285

Country of ref document: EP

REN Ceased due to non-payment of the annual fee